Episode 380: Joey Mason of Claret Capital on Venture Capital, Venture Debt and Europe's Need for Speed

Joey Mason is a Venture Partner in Life Sciences at Claret Capital Partners where he has been since September 2024. He has over 30 years’ experience in the sector, and has significant experience in most segments of the Life Sciences industry – medtech, pharma/ biotech, diagnostics, health IT and techbio. He has served on the boards of 20 private and public companies in Ireland, Europe and the USA.

Our conversation covers the dynamics of venture investing - particularly in the biotech sector, and the differences between the European and US venture ecosystems. He stresses the need for speed and confidence in execution in Europe, and the massive potential that bold investing techniques can have. This is a salutary reminder of the competitive nature of this field.

A special thank you to our sponsors at Baillie Gifford and GCM Grosvenor.

Baillie Gifford is a long-term investment manager, dedicated to discovering the innovations and changemakers that deliver exceptional growth opportunities for you.

GCM Grosvenor is a global alternative asset management solutions provider, with more than $90 billion in assets under management across private equity, infrastructure, real estate, credit, and absolute return strategies. For over 50 years, the firm has helped investors navigate the complexities of alternative investing through a flexible, open-architecture platform.

GCM Grosvenor is also focused on what’s next. Through its Elevate strategy, the firm supports the next generation of private equity leaders, making seed investments in emerging managers and providing the resources, network, and strategic guidance needed to help them grow.

With nearly $800 million raised for its inaugural Elevate Fund, GCM Grosvenor is helping drive innovation and expand access across private markets.

Learn more at gcmgrosvenor.com.